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Abstract. Para-aortic lymph node (PALN) metastasis is 
widely regarded as a systemic disease in cancer. Undetected 
PALN micrometastases during routine hematoxylin and eosin 
(HE) staining may be a cause of poor prognosis following a 
potentially curative pancreatectomy for pancreatic cancer. In 
the present study, paraffin‑embedded PALN tissue blocks from 
99 patients who underwent a pancreatectomy were re-evaluated 
by immunohistochemical staining using cytokeratin (CK)‑19. 
Patients with PALN metastasis were summarized according to 
the clinicopathological data. A total of 484 PALNs (median, 
4.9 nodes per patient; range, 1-19) were evaluated. PALN 
metastases were revealed in eight patients (8.1%) by routine 
HE staining of frozen section biopsies and in one patient 
(1.0%) by HE staining of a permanent section. Only one patient 
(1.0%) demonstrated micrometastasis by IHC; this patient did 
not display any adverse pathological characteristics and had a 
relatively favorable survival period of 41 months. The present 
study concluded that an additional reassessment for microme-
tastasis in PALNs using CK‑19 immunohistochemistry (IHC) 
is not a viable method for determining the survival outcome. 
A careful examination of a frozen section biopsy is sufficient 
for attempting curative surgery.
Introduction
Surgical resection is the only known curative option for 
pancreatic cancer. However, the majority of pancreatic cancers 
are usually diagnosed at advanced stages and only 15-20% of 
patients are candidates for a gross margin-negative pancre-
atectomy (R0) (1). Following a curative resection, distant 
metastases, particularly in the liver, local recurrence and 
peritoneal dissemination frequently occur and these patients 
succumb to their diseases (2,3) The reported five‑year survival 
rate following surgical resection is 12.1-25.0% (1-5) and the 
overall survival rate is considered to be <5%, suggesting that 
pancreatic cancer is one of the most lethal gastrointestinal 
malignancies. 
According to a previous survival analysis of resected 
pancreatic cancers, an R0 was shown to be an independent 
favorable prognostic factor (6-8). Over the past few decades, 
surgeons have attempted to achieve ideal R0 resections by 
extending the surgical margins in the hopes that clearing the 
surrounding soft tissue that contains malignant cells may 
improve the survival outcome. However, several significant 
prospective randomized control studies revealed that extending 
the margins did not result in an additional survival benefit over 
the standard surgery in resectable pancreatic cancer (9-12). 
It has been proposed that a possible underestimation of 
microscopic cancer spreading beyond the surgical field may 
contribute to a poor prognosis following a potentially curative 
surgical treatment (13).
Lymph node metastasis is common in pancreatic 
cancer (14-16) and para-aortic lymph nodes (PALNs) are 
considered to be the final nodes in the systemic lymphatic 
circulation in periampullary cancer (17,18). Although there have 
only been a few studies on the oncological outcome according 
to PALN staging (19‑21), PALN involvement is known to be a 
poor prognostic factor in periampullary tumors (18). However, 
pancreatic surgeons may encounter clinical cases of potentially 
resectable pancreatic tumors with unexpected PALN metas-
tasis that are only identified on intraoperative frozen section 
biopsies. Considering the expected poor prognosis in patients 
with unexpected PALN metastasis and the potential curative 
role of an R0 in pancreatic cancer, the decision to resect must 
be promptly determined in the operating theatre. 
The present study aimed to develop an approach to this 
clinical dilemma. The oncological outcomes in patients with 
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PALN metastasis that were detected by hematoxylin and eosin 
(HE) staining were analyzed in resected pancreatic tumors. 
Immunohistochemistry (IHC) with antibodies against cyto-
keratin (CK)‑19 was used to detect the presence of PALN 
micrometastasis in resected pancreatic ductal adenocarcinoma. 
The role of curative surgery in resectable pancreatic cancer 
with incidentally identified PALN metastasis was further 
investigated using intraoperative frozen section biopsies.
Materials and methods
Study design. The present study retrospectively investigated 
patients who underwent a surgical resection for pancre-
atic ductal adenocarcinoma between January 1999 and 
December 2009 at Yonsei University Health System (Seoul, 
South Korea). During the study period, a total of 1,119 patients 
were diagnosed with pancreatic ductal adenocarcinoma and 
171 patients (15.3%) underwent grossly curative pancre-
atectomies. Of these patients, 99 with available healthy 
paraffin‑embedded tissue blocks of PALN were re‑evaluated 
using IHC. This study was approved by the ethics committee 
of Yonsei University Health System (Seoul, Korea).
Surgery and staging. A pancreaticoduodenectomy or distal 
pancreatectomy with splenectomy was performed, which 
included a resection of the main pancreatic tumor, the asso-
ciated regional lymph nodes, the retroperitoneal soft tissue 
and the PALNs, which allowed for pathological staging. The 
surgical margins, including the bile duct, pancreatic duct, 
peripancreatic soft tissue adjacent to the superior mesenteric 
artery (retroperitoneal margin), duodenum or stomach, were 
evaluated grossly and microscopically in order to determine 
their status. These surgical margins, with the exception of the 
retroperitoneal margin, were analyzed using frozen-sections. 
If the margin was positive for invasive carcinoma, an addi-
tional resection was performed. A pancreatic resection margin 
without evidence of invasive carcinoma was considered an R0. 
The final margin status was noted in the permanent pathology 
report. The TMN stage was evaluated based on the American 
Joint Committee on Cancer (AJCC) Cancer Staging Manual, 
7th edition (23). 
IHC. Three serial sectional cuts from formalin-fixed and 
paraffin‑embedded blocks were studied for IHC. Each of 
the 4-µm sections with 6-µm intervals was prepared for IHC 
staining with CK‑19 (M0888 mouse, monoclonal, 1:100; 
Dako, Copenhagen, Denmark). The IHC was detected using 
a dextran polymer-based, biotin-free visualization system 
(Envision kit; Dako). Previous HE‑stained sections were 
re-evaluated for metastasis and the results were compared 
with the IHC-stained sections by an experienced pathologist. 
Lymph node micrometastasis was defined as metastatic tumor 
cells that were detected by IHC evaluation using antibodies 
against CK, but were missed by routine histological examina-
tion using HE staining. 
Statistical analysis. The primary goal of the study was to 
investigate the clinical significance of PALN micrometastasis 
in resected pancreatic ductal adenocarcinoma. The cumula-
tive survival rates according to overall lymph node metastasis 
(pN stage) and PALN metastasis (LN16) were analyzed. The 
clinicopathological characteristics of the patients with PALN 
metastasis were summarized. By reviewing the medical 
records, recurrence and survival data were obtained. Overall 
survival was defined as the interval between surgery and 
mortality or the final follow‑up visit. The cumulative survival 
rate was calculated using the Kaplan‑Meier method. A 
log‑rank test was used to ascertain the statistically significant 
differences. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Characteristics of patients and resected ductal adenocar-
cinoma. Among the 99 patients (39 females and 60 males), 
the mean age was 61.3 years (range, 39-78). Ductal adeno-
carcinoma was confirmed by microscopic examination in all 
patients. A total of 21 (21.2%) patients underwent a conven-
tional pancreaticoduodenectomy, 64 (64.6%) underwent a 
pylorus-preserving pancreaticoduodenectomy, 13 (13.1%) 
underwent a distal pancreatectomy with splenectomy and one 
(1%) was treated with a total pancreatectomy. Three patients 
were diagnosed with pT1 pancreatic cancer, six with pT2, 
85 with pT3 and five with pT4. The median tumor size was 
2.6 cm (range, 0.5-8.5). There were no R2 resections recorded 
in the medical records. An R1 resection was performed on 
18 patients (18.2%) and an R0 was performed on 81 patients 
(81.8%). 
Retrieved PALN assessment in resected pancreatic cancer. 
A total of 484 PALNs (mean, 4.9 nodes per patient; range, 
1‑19) were evaluated from the available PALN blocks in 
99 patients (Fig. 1). A total of 13 PALNs (2.7%) demonstrated 
metastasis with HE staining in nine patients (eight patients in 
frozen sections and one patient in a permanent section). All 
the eight patients who demonstrated PALN metastasis on the 
HE staining of frozen sections showed a pattern of clustered 
gland formation and desmoplasia, which occupied the entire 
involved node (Fig. 2A). The histology of the patient who had 
PALN metastasis confirmed by HE staining of the perma-
nent section, which was not detected in the frozen section, 
Figure 1. Retrieved PALN assessment in resected pancreatic cancer. A total 
of 484 PALNs (mean, 4.9 nodes per patient; range, 1-19) were evaluated from 
the available PALN blocks of 99 patients. Nine patients were identified to 
exhibit PALN metastasis on routine HE staining (eight patients in frozen 
sections and one patient in a permanent section). Only one additional patient 
immunohistochemically demonstrated micrometastasis in a PALN that was 
not detected otherwise. PALN, para-aortic lymph node; HE, hematoxylin and 
eosin; IHC, immunohistochemistry.
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revealed a pattern of scattered small gland formation without 
desmoplasia (Fig. 2B). IHC reassessment for all 484 PALNs 
revealed that only one additional patient immunohistochemi-
cally demonstrated micrometastasis in a PALN that was not 
detected otherwise. The CK‑19 staining revealed micrometas-
tases in an ~46-µm isolated pattern (Fig. 2C). 
Oncological outcomes of pancreatic cancer with PALN metas-
tasis. The survival rate did not significantly differ based on 
the pN staging in the present study. The median survival time 
was 34 months (95% CI, 24.3-43.7) for the pN0 tumors and 
30 months (95% CI,: 20.3-39.7) for the pN1 tumors (P=0.223; 
Fig. 3A). However, a statistically significant difference was 
observed in the survival time based on PALN involvement, 
confirmed by routine HE evaluation. The median survival 
time was 31 months (95% CI, 23.9-38.1) in patients without 
PALN metastases versus 17 months (95% CI, 12.8-21.6) for 
patients with PALN metastases (P=0.008; Fig. 3B).
Table I shows the characteristics of the patients with 
PALN metastasis. Cases 1-8 were the patients who showed 
PALN metastasis on HE staining of the frozen sections. These 
patients exhibited large metastatic tumors in the PALNs 
(median size, 2 mm; range, 0.8-12 mm) with clustered gland 
patterns and extensive desmoplasia. Case 9, who had PALN 
metastasis confirmed by HE staining of the permanent section, 
had relatively small metastatic tumors in the PALNs with a 
pattern of scattered small gland formation and no desmoplasia. 
Lastly, case 10, who exhibited PALN detected only by IHC 
staining, possessed extremely small isolated metastatic tumors 
in the PALNs. All patients who exhibited PALN metastasis 
confirmed by HE staining (cases 1-9) had other aggres-
sive tumor characteristics, including other regional lymph 
node metastasis (N1) and lymphovascular and/or perineural 
invasions, and one patient demonstrated positive resection 
margins (R1). Case 10 exhibited less aggressive adverse patho-
logical features. The median survival time of cases 1-8 was 
17.5 months (range, 10-39). The survival times of cases 9 and 
10 were 34 and 41 months, respectively. 
Discussion
Based on the results of the present study, additional IHC 
using CK‑19 antibodies to detect PALN micrometastases in 
resected pancreatic ductal adenocarcinoma is not an appro-
priate method to predict prognosis. While the rate of PALN 
metastasis has been reported to be 6-26% (24-27), there may 
be a surgical selection bias that is affecting these numbers. 
Figure 2. PALN metastasis in pancreatic cancer. (A) PALN metastasis defined 
in HE staining of frozen biopsy and permanent sections. Note a pattern of 
clustered gland formation (thick white arrow) and desmoplasia (thick black 
arrow) in the involved node (HE; magnification, x40). (B) PALN metastasis 
defined in only HE staining of a permanent section, which was missed in the 
frozen section, revealed a pattern of scattered small gland formation without 
desmoplasia. This image of this slide was captured following IHC staining 
to show the metastatic pattern more precisely (CK‑19; magnification, x40). 
(C) Micrometastasis of PALN demonstrated in IHC staining showing a small 
size and isolated pattern (thin black arrow; CK‑19; magnification, x100). 
PALN, para‑aortic lymph node; HE, hematoxylin and eosin; CK, cytokeratin.
Figure 3. Overall survival according to pN-stage and PALN metastasis in 
resected ductal adenocarcinoma of the pancreas. (A) No survival difference 
was noted according to the pN-stage. (B) However, PALN metastasis dem-
onstrated a difference in survival among the patients with pN1 pancreatic 
cancer. PALN, para-aortic lymph node.
  A
  B
  C
  A
  B
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For example, pancreatectomies are generally not performed 
when PALN metastasis is strongly suggested in pre-operative 
imaging studies, with observations that include large and 
conglomerated lymph nodes in the retroperitoneal para-aortic 
area. As a result, only nine patients (9.1%) exhibited PALN 
metastases in routine intraoperative frozen section biopsies 
and permanent pathological reports, and only one additional 
patient (1.0%) was shown to have PALN micrometastasis upon 
CK‑19 staining. Therefore, the incidence of PALN metastasis 
was observed to be 10.1%. An accurate staging of PALN 
metastasis conducted by a careful pathological examination 
with routine HE staining is considered to be sufficient for 
tumor staging and is useful in predicting prognosis.
Due to the infrequency of resectable pancreatic ductal 
adenocarcinoma, only a few studies have demonstrated the 
clinical significance of PALN metastasis in resected pancre-
atic cancer. Doi et al (20) analyzed the clinicopathological 
factors in patients with short-term survival who underwent 
margin-negative radical extended pancreaticoduodenectomy. 
PALN metastasis was concluded to be the only independent 
factor for poor prognosis and ~85% of patients with PALN 
metastasis succumbed within one year. Shimada et al (28) 
reported that PALN metastasis was the definitive predictor 
of recurrence and a shorter survival outcome (<12 months). 
Yoshida et al (27) also identified the clinicopathological 
features and surgical outcomes of PALN-positive periam-
pullary adenocarcinoma, and recommended performing 
intraoperative PALN sampling for frozen section biopsies. 
The study concluded that radical pancreatectomy with 
extended soft tissue clearance should not be performed in 
PALN-positive patients due to a poor oncological outcome. 
According to the data set of the present study, all eight patients 
whose frozen section biopsies confirmed PALN metastasis 
eventually developed tumor recurrences within 12 months of 
surgery and seven succumbed to the disease within two years 
(median survival, 17.5 months; Table I). These eight patients 
had significantly shorter survival periods compared with those 
patients with regional lymph node metastasis without PALN 
involvement (P<0.008; Fig. 2B).
Notably, a few cases of long-term survival in patients 
with PALN metastasis in resected pancreatic cancer have 
been reported (21,29). Although, as noted previously, 
studies suggest a poor outcome in PALN-positive resected 
pancreatic cancer, the majority do not consider the associ-
ated characteristics of PALN metastasis. Shimada et al (28), 
however, observed that PALN metastasis was notably associ-
ated with elevated CA 19-9 levels, a larger tumor size and 
positive surgical margins. Peritoneal cytology was correlated 
with PALN metastasis in the study (P=0.09). Furthermore, 
Yamada, et al (30) concluded that radical surgery may still 
have value for certain populations of patients with PALN 
metastasis, such as those aged 60 years or older, patients with 
tumors of <4 cm and those without portal vein involvement. 
The study also suggested that patients with one lymph node 
positive for PALN metastasis tended to have an improved 
prognosis compared with those with two or more positive 
PALN metastases (P=0.14). 
Although the present data set was rather small and selec-
tion bias may have been a factor, it suggests a potential role 
for curative surgery in certain patient groups with resectable 
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pancreatic cancer and PALN involvement. In spite of the poor 
prognosis in patients who demonstrated PALN metastases 
observed in routine HE staining, relatively longer survivals 
were noted in several patients (Table I). Considering a poor 
median survival time of 5-11 months for unresectable pancre-
atic tumors without distant metastases (31), the oncological 
outcomes of the patients included in the present study are 
thought to be significant, given that curative surgery is the only 
intervention that may lead to long-term survival in pancreatic 
cancer. Given the current state of continually improving 
surgical techniques, perioperative management and adjuvant 
therapies for pancreatic cancer, the findings of the present 
study may expand the role of surgery in managing pancreatic 
cancer, even when PALN metastasis is unexpectedly identified 
intraoperatively. 
According to the present results, all eight patients with 
PALN metastasis confirmed in frozen section biopsies showed 
large metastatic tumor sizes and clustered gland patterns with 
extensive desmoplasia. However, one patient exhibited PALN 
metastasis that was only identified in routine HE staining of 
the permanent section, but was missed in the frozen section. 
This section demonstrated a relatively small size gland pattern 
without desmoplasia or extensive involvement of the node 
(Fig. 2). In spite of these histological differences, all of the 
patients possessed other adverse pathological factors including 
regional lymph node metastasis, perineural invasion and 
lymphovascular invasion (Table I). The patient whose PALN 
metastasis was only detected with IHC (case 10) demonstrated 
a small, isolated metastasis with less aggressive adverse 
pathological features. This patient had a relatively long-term 
survival of 41 months. Notably, despite a small sample size, a 
correlation was observed between the tumor burden of PALN 
metastasis and the survival outcome. A small PALN metas-
tasis, which is either undetectable in frozen biopsy or only 
noticeable in immunostaining, may lead to a longer survival 
time. 
The present study defined lymph node micrometastasis as 
metastatic tumor cells that are only detectable by IHC staining. 
However, a universal definition and clinical significance of 
micrometastasis for pancreatic cancer is still lacking. There 
are more established characterizations of micrometastasis 
in breast (32), esophageal (33,34), stomach (35) and colon 
cancers (36,37) Therefore, the micrometastasis of pancreatic 
cancer requires further study. 
In summary, PALN metastasis that is undetected by routine 
HE staining in frozen section biopsy, but identified using 
CK‑19 immunostaining, may indicate a relatively lower tumor 
burden. This may be associated with less aggressive behavior 
and a favorable prognosis in pancreatic cancer. Therefore, 
routine HE staining is thought to be sufficient for predicting 
prognosis. Additionally, in cases where PALN metastasis is 
unexpectedly identified in intraoperative frozen section biop-
sies, patients may benefit from curative radical surgery with 
aggressive adjuvant chemotherapy. However, further large 
volume investigations are warranted to validate this issue.
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